K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML)

被引:0
|
作者
Maria J. Carnicer
Adriana Lasa
Marcus Buschbeck
Elena Serrano
Maite Carricondo
Salut Brunet
Anna Aventin
Jorge Sierra
Luciano Di Croce
Josep F. Nomdedeu
机构
[1] Universitat Autònoma de Barcelona,Department of Hematology, Hospital de la Santa Creu i Sant Pau
[2] Universitat Pompeu Fabra,Centre de Regulacio Genomica (CRG)
[3] ICREA and Centre de Regulacio Genomica (CRG),Laboratori d’Hematologia, Hospital de la Santa Creu i Sant Pau
[4] Universitat Autònoma de Barcelona,undefined
来源
Annals of Hematology | 2008年 / 87卷
关键词
CEBPA; Acute myeloid leukemia; Mutations;
D O I
暂无
中图分类号
学科分类号
摘要
The CEBPA gene codes for a transcription factor that has a pivotal role in controlling proliferation and differentiation of myeloid progenitors. Acquired CEBPA mutations have been found in acute myeloid leukemias (AML) with a good prognosis, and most of these patients have a normal karyotype. In this paper, we report four cases that displayed the same K313dup in the CEBPA gene. All four had an AML-M1 with CD7 positivity and T-cell receptor gamma chain (TCR-γ) rearrangement. This mutation could represent nearly 10% of all CEBPA mutations described to date. K313dup disappeared in samples from patients in complete remission. In transfected cells, the K313dup mutant had reduced protein stability with respect to the wild-type protein. K313dup seems to be selected in leukemic cells, and its frequency in other AML series could be determined using the screening method reported in this paper.
引用
收藏
页码:819 / 827
页数:8
相关论文
共 50 条
  • [1] K313dup is a recurrent CEBPA mutation in de novo acute myeloid leukemia (AML)
    Carnicer, Maria J.
    Lasa, Adriana
    Buschbeck, Marcus
    Serrano, Elena
    Carricondo, Maite
    Brunet, Salut
    Aventin, Anna
    Sierra, Jorge
    Di Croce, Luciano
    Nomdedeu, Josep F.
    ANNALS OF HEMATOLOGY, 2008, 87 (10) : 819 - 827
  • [2] CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia
    Lin, T-C
    Hou, H-A
    Chou, W-C
    Ou, D-L
    Yu, S-L
    Tien, H-F
    Lin, L-I
    LEUKEMIA, 2011, 25 (01) : 32 - 40
  • [3] CEBPA methylation as a prognostic biomarker in patients with de novo acute myeloid leukemia
    T-C Lin
    H-A Hou
    W-C Chou
    D-L Ou
    S-L Yu
    H-F Tien
    L-I Lin
    Leukemia, 2011, 25 : 32 - 40
  • [4] ASXL2 mutation is recurrent in non-de novo AML1-ETO-negative acute myeloid leukemia
    Zhang, Xiang
    Jin, Jie
    Yu, Wenjuan
    ANNALS OF HEMATOLOGY, 2019, 98 (11) : 2621 - 2623
  • [5] ASXL2 mutation is recurrent in non-de novo AML1-ETO-negative acute myeloid leukemia
    Xiang Zhang
    Jie Jin
    Wenjuan Yu
    Annals of Hematology, 2019, 98 : 2621 - 2623
  • [6] The Clinical and Biological Characterization of De Novo Acute Myeloid Leukemia (AML) with GATA2 Mutation
    Tien, Feng-Ming
    Chou, Wen-Chien
    Hou, Hsin-An
    Chiu, Yu-Chiao
    Chuang, Eric Y.
    Chen, Chien-Yuan
    Tang, Jih-Luh
    Yao, Ming
    Huang, Shang-Yi
    Ko, Bor-Sheng
    Hsu, Szu-Chun
    Wu, Shang-Ju
    Tsay, Woei
    Tien, Hwei-Fang
    BLOOD, 2015, 126 (23)
  • [7] Nucleophosmin mutation in de-novo acute myeloid leukemia
    Rastogi, Pulkit
    Naseem, Shano
    Varma, Neelam
    Varma, Subhash
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 (01) : 77 - 85
  • [8] Germline CEBPA mutation in familial acute myeloid leukemia
    Boada, Matilde
    Ines Catalan, Ana
    Ottati, Carolina
    Bentancour, Florencia
    Lens, Daniela
    Guillermo, Cecilia
    Grille, Sofia
    HEMATOLOGY REPORTS, 2021, 13 (03)
  • [9] CEBPA mutations in patients with de novo acute myeloid leukemia: data analysis in a Chinese population
    Su, Long
    Gao, Sujun
    Liu, XiaoLiang
    Tan, Yehui
    Wang, Lu
    Li, Wei
    ONCOTARGETS AND THERAPY, 2016, 9 : 3399 - 3403
  • [10] Expression and prognostic significance of survivin in de novo acute myeloid leukemia (AML).
    Adida, C
    Recher, C
    Raffoux, E
    Daniel, MT
    Taksin, AL
    Rousselot, P
    Sigaux, F
    Degos, L
    Altieri, DC
    Dombret, H
    BLOOD, 2000, 96 (11) : 698A - 698A